Ambroxol HCL sales will expand through 2036, with respiratory tract disorders holding 82.0% share in 2026. Powder form accounts for 72.0% of demand. The market was valued at USD 2.5 million in 2025, stands at USD 2.58 million in 2026 and reaches USD 3.37 million by 2036 globally.